Want to join the conversation?
The generic drugmaker $MYL reported a fall in 3Q15 earnings due to higher operating expenses and tax benefit recorded in the previous year quarter on merger of its units into Mylan Labs. Net earnings fell to $428.6MM or $0.83 per share from $499.1MM or $1.26 per share last year. Revenue grew to $2.7Bil from $2.08Bil. Adjusted EPS grew 23% to $1.43.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.
Well this is big! I don’t know if it’s someone’s monopoly or genuine excitement, but either way, $CSX is up 23% after market closed. I heard some activist investor is going to blow big money into CSX Corp. Anyone mind explaining?